Eli Lilly and Company ($LLY) Stock Forecast: Up 3.7% Today

What is Eli Lilly and Company?

Eli Lilly (LLY) is a pharmaceutical company known for its innovative drug developments. Today, the stock experienced a strong bullish movement amidst market fluctuations.

Why is Eli Lilly and Company going up?

LLY stock is up 3.7% on Dec 11, 2025 15:41

• Eli Lilly's bullish movement can be attributed to the positive results from its obesity drug trial, showcasing the company's commitment to developing effective treatments.
• The removal of CVS from its employee drug plan following a drug snub highlights the competitive landscape in the pharmaceutical industry and Eli Lilly's strategic decisions to maintain market position.
• Market rumors of a potential takeover by Eli Lilly have also contributed to the stock's surge, indicating investor confidence in the company's growth strategy and potential acquisitions.
• Overall, Eli Lilly's strong performance reflects a combination of successful drug trials, strategic business decisions, and market speculations driving the stock's upward momentum.

LLY Price Chart

LLY Technical Analysis

LLY News

Oracle, Adobe and Broadcom fall premarket; Eli Lilly gains

U.S. stock futures pulled back Thursday following the Federal Reserve's expected rate cut and as the earnings season concludes. Oracle slumped on a missed forecast, while Eli Lilly rose on strong obesity drug trial results, contrasting with declines for Adobe and Broadcom ahead of its earnings. Other movers included Gemini Space Station soaring on CFTC approval, Oxford Industries falling due to a cut forecast, and Ciena gaining on exceeding expectations.

https://www.investing.com/news/stock-market-news/oracle-adobe-and-broadcom-fall-premarket-eli-lilly-gains-4403165

Incyte stock hits 52-week high at 108.81 USD

Incyte Corporation's stock reached a new 52-week high of $108.81, reflecting a 35.01% appreciation over the past year and underscoring strong investor confidence. This performance is bolstered by strategic moves, including an exclusive option to acquire Prelude Therapeutics’ JAK2V617F JH2 inhibitor program, and positive analyst ratings from TD Cowen, Oppenheimer, and Guggenheim. The company's robust Q3 revenues surpassed estimates, further contributing to its strong market position.

https://www.investing.com/news/company-news/incyte-stock-hits-52week-high-at-10881-usd-93CH-4352407

Eli Lilly Removes CVS from Employee Drug Plan Following Weight-Loss Drug Snub

Eli Lilly has removed CVS Health Corp. from its employee drug plan, effective January 1, in response to CVS's decision to exclude Lilly's weight-loss drug Zepbound from its preferred formulary. This move, favouring Novo Nordisk's Wegovy, highlights escalating tensions over drug pricing, patient access, and the competitive landscape between pharmaceutical companies and pharmacy benefit managers (PBMs). The decision has significant implications for Eli Lilly, the stock market, and broader pharmaceutical industry dynamics, emphasizing cost containment pressures and the negotiation power of PBMs.

https://meyka.com/blog/eli-lilly-removes-cvs-from-employee-drug-plan-following-weight-loss-drug-snub/

Structure Therapeutics’ Leap: What’s Sparking the Surge?

Structure Therapeutics Inc. (NASDAQ: GPCR) has experienced a significant stock surge following promising Phase 2b clinical trial results for its drug candidate aleniglipron, intended for obesity treatment. Analysts are raising price targets, and the company announced a $500M public offering, reflecting increased investor confidence. The drug's efficacy and the company's strategic financial management are positioning it as a strong contender in the pharmaceutical market, with a potential U.S. launch by 2028.

https://stockstotrade.com/news/structure-therapeutics-inc-gpcr-news-2025_12_10/

What's Happening With French Biotech Abivax Stock On Wednesday?

Abivax SA's stock is trading higher on Wednesday due to market rumors of a potential takeover by U.S. pharma giant Eli Lilly and Co. The company's stock has surged over 1,500% in the past six months, driven significantly by positive Phase 3 trial results for its ulcerative colitis treatment, obefazimod. Eli Lilly has also been speculated to be preparing for other major acquisitions, including Viking Therapeutics Inc.

https://www.benzinga.com/m-a/25/12/49313094/whats-happening-with-french-biotech-abivax-stock-on-wednesday

Trending Today

CleanSpark Inc ($CLSK) Stock Forecast: Up 5.3% Today

QuantumScape Corp. ($QS) Stock Forecast: Up 5.1% Today

Carnival Corporation ($CCL) Stock Forecast: Up 6.0% Today

Royal Caribbean Cruises Ltd. ($RCL) Stock Forecast: Up 7.5% Today

Elevance Health Inc. ($ELV) Stock Forecast: Up 6.0% Today

Mosaic Company (The) ($MOS) Stock Forecast: Up 6.7% Today

Alcoa Corporation ($AA) Stock Forecast: Up 5.8% Today

Oracle Corporation ($ORCL) Stock Forecast: Down 11.5% Today

Vaulta (prev.EOS) ($A) Crypto Forecast: Down 5.1% Today

Shiba Inu ($SHIB) Crypto Forecast: Down 5.3% Today

Eli Lilly and Company Price History

15.07.2025 - LLY Stock was up 5.1%

• Eli Lilly stock climbed significantly today, driven by several factors:
• The UK monthly price increase for Mounjaro's highest dose and the pricing adjustment in India's Mounjaro Kwikpen likely contributed to the positive movement.
• Insider moves within the company, such as bold buys and record sales, may have boosted investor confidence.
• Speculation around undervalued healthcare stocks, including Eli Lilly, could have attracted buyers looking for potential growth opportunities.

26.07.2025 - LLY Stock was up 5.0%

• Eli Lilly stock surged after positive results from its oral GLP-1 pill trial, which demonstrated impressive weight loss benefits and blood sugar level reductions.
• The success of the weight-loss pill trial has fueled investor optimism and confidence in Eli Lilly's future growth prospects.
• Despite a setback with its orforglipron pill, the company's robust late-stage pipeline continues to support expectations for sustained growth and innovation in the pharmaceutical sector.
• The investigation by the Portnoy Law Firm into Eli Lilly's activities does not seem to have impacted the stock's bullish momentum, indicating that investors are primarily focused on the positive trial results and growth potential.

30.09.2025 - LLY Stock was up 2.0%

• Eli Lilly (LLY) surpassed Q3 earnings and revenue expectations, demonstrating robust financial performance.
• Collaboration with NVIDIA on a high-performance supercomputer underscores Lilly's dedication to technological advancements in pharmaceutical research.
• Aggressive acquisitions in the biotech and gene therapy sectors signal a strategic effort to diversify its pipeline and spur long-term growth.
• Positive views from Wall Street and Buy recommendations are boosting investor confidence and contributing to the upward trend of the stock.

29.06.2025 - LLY Stock was down 5.2%

• The company witnessed a bearish movement in its stock performance.
• Reduced sales growth outlook of a competitor and concerns over illegal weight-loss drug imports impacting a specific drug category may have influenced overall market sentiment towards the company.
• Despite positive news of a drug recommendation for Alzheimer's disease, it may not have fully offset the prevailing negative market sentiment.
• The bearish stance taken by investors through options trading likely contributed to the stock's decline.

29.06.2025 - LLY Stock was down 6.1%

• The decline in Eli Lilly's stock could be linked to investors taking a bearish stance in options trading, as shown by publicly available options history.
• Concerns raised by Congress about the illegal import of weight-loss drugs from China, which also mentioned Eli Lilly, may have further dampened investor sentiment.
• While Eli Lilly received positive news of early Alzheimer's drug approval recommendation in Europe, the market seemed more influenced by general pessimism and regulatory risks.
• The conclusion of the Verve tender offer involving Eli Lilly likely impacted investor sentiment and contributed to the stock's bearish movement.

29.06.2025 - LLY Stock was down 6.7%

• The bearish movement in LLY stock could be attributed to concerns raised by Congress over illegal weight-loss drug imports from China, which might impact the company's reputation and sales.
• Despite the positive news of Eli Lilly's early Alzheimer's drug recommendation for approval in Europe, the market might be reacting more to the potential safety risks associated with illegal drug imports.
• Investors might be cautious about the upcoming Q2 earnings report, especially regarding the performance of Eli Lilly's oncology drugs, as any underperformance could have contributed to the bearish trend.
• The expiration of the Verve tender offer might also be a factor in the stock's movement, signaling potential shifts in the company's strategic partnerships or future developments.

05.10.2025 - LLY Stock was up 5.0%

• Eli Lilly's $149 obesity drug deal with the White House has excited investors, fueling optimism for increased revenue and market share.
• The company's announcement of a substantial European manufacturing expansion for oral medicine has likely bolstered investor confidence in its growth potential.
• Surpassing expectations for third-quarter earnings and raising the annual forecast have contributed to the positive outlook on Eli Lilly, attracting more investors.
• The impressive performance of key drugs like Mounjaro and Zepbound, resulting in a notable revenue increase, has further reinforced Eli Lilly's growth prospects and driven up the stock price.

07.07.2025 - LLY Stock was down 13.3%

• Despite surpassing earnings and revenue estimates in Q2, Eli Lilly's stock experienced a bearish movement.
• The disappointment in the weight loss results of Orforglipron compared to financial forecasts may have contributed to the stock's decline.
• Threats of imposing high tariffs on pharmaceutical imports could have added uncertainty to the market, impacting Eli Lilly's stock negatively.
• The reversal of early weakness and the climb of 1.8% towards the end of the day could indicate some resilience in the stock, potentially driven by positive trading signals and smart money inflow.

01.09.2025 - LLY Stock was up 11.2%

• Eli Lilly's stock (LLY) has seen a bullish trend, driven by encouraging recommendations from financial analysts on Wall Street, signaling a buy outlook among investors.
• Remarkably, Pfizer's agreement with the Trump administration concerning drug pricing has had a constructive impact on the pharmaceutical industry, including companies like Eli Lilly.
• Investor confidence, potentially from institutions or high-net-worth individuals, in Eli Lilly has intensified the upward trajectory of its stock.
• Additionally, Amgen's enhancement of its U.S. manufacturing footprint amid evolving tariff regulations could have indirectly contributed to the positive market sentiment around pharmaceutical firms like Eli Lilly.

01.09.2025 - LLY Stock was up 8.4%

• Eli Lilly's stock surged due to an announcement by President Donald Trump regarding a deal with Pfizer, which included the 'TrumpRx' platform aimed at reducing drug prices. This news boosted investor confidence in the pharmaceutical sector.
• The partnership between Pfizer and Washington had a significant impact on the industry, leading to companies like Eli Lilly benefiting from the positive market sentiment.
• Furthermore, bullish bets from high-net-worth investors, as reflected in publicly available options history, added to the upward momentum in Eli Lilly's stock.
• The overall optimism surrounding Eli Lilly, along with strategic expansions and favorable analyst recommendations, played key roles in the stock's impressive performance on the day.

11.11.2025 - LLY Stock was up 3.7%

• Eli Lilly's bullish movement can be attributed to the positive results from its obesity drug trial, showcasing the company's commitment to developing effective treatments.
• The removal of CVS from its employee drug plan following a drug snub highlights the competitive landscape in the pharmaceutical industry and Eli Lilly's strategic decisions to maintain market position.
• Market rumors of a potential takeover by Eli Lilly have also contributed to the stock's surge, indicating investor confidence in the company's growth strategy and potential acquisitions.
• Overall, Eli Lilly's strong performance reflects a combination of successful drug trials, strategic business decisions, and market speculations driving the stock's upward momentum.

30.08.2025 - LLY Stock was up 5.3%

• Eli Lilly (LLY) stock surged due to positive market sentiment and investor confidence in the company's growth prospects.
• The bullish stance taken by investors, including institutions and high-net-worth individuals, further boosted the stock's performance.
• Analysts' optimistic recommendations and the company's strategic position in the pharmaceutical industry also contributed to the bullish movement.
• While competitors like Novo Nordisk, Amgen, and AstraZeneca made headlines, it was Lilly's own positive outlook that drove its stock price higher today.